Selecta Biosciences is laying off more than one-third of its workforce. The cuts come as Selecta seeks to eke out its cash reserves and advance a gout drug that disappointed investors in phase 2.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,